Cargando…
Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
BACKGROUND: Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression)...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109776/ https://www.ncbi.nlm.nih.gov/pubmed/27842532 http://dx.doi.org/10.1186/s12888-016-1115-z |
_version_ | 1782467604905984000 |
---|---|
author | Malaguarnera, Giulia Bertino, Gaetano Chisari, Giuseppe Motta, Massimo Vecchio, Michele Vacante, Marco Caraci, Filippo Greco, Carmela Drago, Filippo Nunnari, Giuseppe Malaguarnera, Michele |
author_facet | Malaguarnera, Giulia Bertino, Gaetano Chisari, Giuseppe Motta, Massimo Vecchio, Michele Vacante, Marco Caraci, Filippo Greco, Carmela Drago, Filippo Nunnari, Giuseppe Malaguarnera, Michele |
author_sort | Malaguarnera, Giulia |
collection | PubMed |
description | BACKGROUND: Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression) were associated with work ability in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b (Peg–IFN) and Ribavirin (RBV). METHODS: Thirty-one patients (Group A) with chronic hepatitis and other 31 subjects in Group B were recruited in a randomized, prospective, placebo controlled, double blind clinical trial. Group A received 1.5 mg/kg per week of Peg–IFN plus RBV and placebo, while Group B received the same dosage of Peg–IFN plus RBV plus association of Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg in pills for 12 months. All subjects underwent to laboratory exams and questionnaires to evaluate depression (Beck Depression Inventory - BDI), anxiety (State-trait anxiety inventory - STAI) and work ability (Work ability Index - WAI). RESULTS: The comparison between group A and group B showed significant differences after 6 months in ALT (P < 0.001), and viremia (P < 0.05), after 12 months in ALT (P < 0.001), and AST (P < 0.001), at follow up in AST (P < 0.05), and ALT (P < 0.001). Significant difference were observed after 1 month in WAI (p < 0.001) and BDI (P < 0.05), after 6 months in WAI (P < 0.05) and STAI (P < 0.05), after 12 months and at follow up in WAI, STAI and BDI (p < 0.01). CONCLUSIONS: The supplementation with Silybin-vitamin E -phospholipids complex increased work ability and reduced depression and anxiety in patients treated with Peg–IFN and RBV. TRIAL REGISTRATION: NCT01957319, First received: September 25, 2013. Last updated: September 30, 2013 (retrospectively registered). |
format | Online Article Text |
id | pubmed-5109776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-51097762016-11-28 Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability Malaguarnera, Giulia Bertino, Gaetano Chisari, Giuseppe Motta, Massimo Vecchio, Michele Vacante, Marco Caraci, Filippo Greco, Carmela Drago, Filippo Nunnari, Giuseppe Malaguarnera, Michele BMC Psychiatry Research Article BACKGROUND: Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression) were associated with work ability in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b (Peg–IFN) and Ribavirin (RBV). METHODS: Thirty-one patients (Group A) with chronic hepatitis and other 31 subjects in Group B were recruited in a randomized, prospective, placebo controlled, double blind clinical trial. Group A received 1.5 mg/kg per week of Peg–IFN plus RBV and placebo, while Group B received the same dosage of Peg–IFN plus RBV plus association of Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg in pills for 12 months. All subjects underwent to laboratory exams and questionnaires to evaluate depression (Beck Depression Inventory - BDI), anxiety (State-trait anxiety inventory - STAI) and work ability (Work ability Index - WAI). RESULTS: The comparison between group A and group B showed significant differences after 6 months in ALT (P < 0.001), and viremia (P < 0.05), after 12 months in ALT (P < 0.001), and AST (P < 0.001), at follow up in AST (P < 0.05), and ALT (P < 0.001). Significant difference were observed after 1 month in WAI (p < 0.001) and BDI (P < 0.05), after 6 months in WAI (P < 0.05) and STAI (P < 0.05), after 12 months and at follow up in WAI, STAI and BDI (p < 0.01). CONCLUSIONS: The supplementation with Silybin-vitamin E -phospholipids complex increased work ability and reduced depression and anxiety in patients treated with Peg–IFN and RBV. TRIAL REGISTRATION: NCT01957319, First received: September 25, 2013. Last updated: September 30, 2013 (retrospectively registered). BioMed Central 2016-11-15 /pmc/articles/PMC5109776/ /pubmed/27842532 http://dx.doi.org/10.1186/s12888-016-1115-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Malaguarnera, Giulia Bertino, Gaetano Chisari, Giuseppe Motta, Massimo Vecchio, Michele Vacante, Marco Caraci, Filippo Greco, Carmela Drago, Filippo Nunnari, Giuseppe Malaguarnera, Michele Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability |
title | Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability |
title_full | Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability |
title_fullStr | Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability |
title_full_unstemmed | Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability |
title_short | Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability |
title_sort | silybin supplementation during hcv therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109776/ https://www.ncbi.nlm.nih.gov/pubmed/27842532 http://dx.doi.org/10.1186/s12888-016-1115-z |
work_keys_str_mv | AT malaguarneragiulia silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability AT bertinogaetano silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability AT chisarigiuseppe silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability AT mottamassimo silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability AT vecchiomichele silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability AT vacantemarco silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability AT caracifilippo silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability AT grecocarmela silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability AT dragofilippo silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability AT nunnarigiuseppe silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability AT malaguarneramichele silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability |